Johnson & Johnson http://www.jnj.com/
Robert Wood Johnson
concluded there ought to be a better way. Mr. Johnson joined with
his two brothers, James Wood and Edward Mead Johnson, who had
formed a partnership in 1885. Operations began in New Brunswick,
New Jersey, in 1886 with 14 employees on the fourth floor of a
small building that once was a wallpaper factory. In 1887 the
Company was incorporated as Johnson & Johnson.
Johnson & Johnson
went from a privately-held company to one publicly traded on the
New York Stock Exchange in 1944.
In 1982 and again in 1986
TYLENOL®, a product of our McNeil Consumer
& Specialty Pharmaceuticals subsidiary, was altered by
unknown individuals who placed deadly cyanide in the capsule form
of the product. The result was the death of seven people in 1982.
The product was voluntarily recalled and Johnson & Johnson
took a $100 million charge against earnings.
& Johnson Pfizer発表 Pfizer方針
Johnson to Acquire Pfizer Consumer Healthcare; Combination
Creates World's Premier Consumer Health Care Company
All Cash Transaction is Valued at $16.6 Billion
Johnson & Johnson,
the world's most comprehensive and broadly based manufacturer of
health care products, today announced that it has entered into a
definitive agreement to acquire Pfizer Consumer
billion in cash.
The Johnson & Johnson Board of Directors has given approval
to the transaction. Closing is subject to customary clearances,
including the Hart-Scott-Rodino Antitrust
and European Union merger control regulation. The transaction is
expected to close by the end of 2006.
The Pfizer Consumer Healthcare business adds a diverse portfolio
of strong, growing, enduring brands that provide Johnson &
Johnson with leadership positions in nine
additional categories, including large new segments such as
smoking cessation and mouthwash.
The combined portfolio of OTC brands will solidify the global
market-leading position of Johnson & Johnson's OTC franchise.
Under the terms of the agreement, Johnson & Johnson will also
acquire the U.S. OTC switch rights to ZYRTEC - Pfizer's once-a-day,
non-sedating prescription antihistamine抗ヒスタミン剤, upon patent expiration.
Pfizer Reaches Agreement to Sell Its Consumer
Healthcare Business to Johnson & Johnson for $16.6
||Company Will Use After-Tax
Proceeds to Invest in New Products and Innovative
Technologies and Enhance Shareholder Returns
||Pfizer Now Expects to
Purchase up to $17 Billion in Stock in 2006-7
||CEO McKinnell: 'We Have
Taken Another Important Step to Create Value for Our
Shareholders While Transforming Our Company'
Colleagues 'Have Done a Superb Job in Building an
Pfizer Inc said today that it has reached a
definitive agreement to sell its Pfizer Consumer Healthcare
(PCH) business to Johnson & Johnson for $16.6 billion in
cash, resulting in about $13.5 billion in after-tax proceeds.
The agreement, approved by the Pfizer Board of
Directors, completes a review of strategic options
for the consumer business that Pfizer initiated in February.
Antitrust Improvements Actの概要
Jun 2, 2016 J&J
Johnson & Johnson Announces Agreement to
Acquire Vogue International
Acquisition Strengthens Position in Hair Care
Johnson & Johnson today announced that Johnson & Johnson Consumer Inc. has
entered into a definitive agreement to acquire Vogue
International, a privately held company focused on the marketing,
development and distribution of salon-influenced and nature inspired
hair care and other personal care products, for
approximately $3.3 billion in cash. The acquisition
will include the OGX® collection of shampoos, conditioners, treatments, styling
products, body care and bath products, the FX™ line of hair styling products,
and the Proganix® and Maui Moisture hair care lines.
"Our acquisition of Vogue International's full line of leading advanced hair
care products sold in the U.S. and in 38 countries will strengthen our global
presence in this important category. Vogue International's commitment to
quality, innovation, and consumer preference complement our Consumer portfolio,
while also presenting attractive hair care category growth opportunities for
Johnson & Johnson," said Jorge Mesquita, Worldwide Chairman, Consumer, Johnson &
The closing is subject to antitrust clearance and other customary closing
conditions. The transaction is expected to close during the third quarter of
Upon closing, the transaction is not expected to impact the 2016 sales or
earnings guidance ranges that Johnson & Johnson announced on April 19, 2016.
September 16, 2016
Johnson & Johnson Announces Agreement to Acquire Abbott Medical Optics
Johnson & Johnson today announced a
definitive agreement to acquire Abbott Medical Optics
(AMO), a wholly-owned subsidiary of Abbott Laboratories, for
$4.325 billion in cash. AMO reported sales of $1.1
billion for 2015. The acquisition will include ophthalmic products in three
business segments: cataract surgery白内障手術,
laser refractive surgery レーザー屈折矯正手術and
consumer eye health.
"Eye health is one of the largest, fastest growing and most underserved segments
in health care today,” said Ashley McEvoy, Company Group Chairman, responsible
for Johnson & Johnson’s Vision Care Companies. “With the acquisition of Abbott
Medical Optics’ strong and differentiated surgical ophthalmic portfolio, coupled
with our world-leading ACUVUE® contact lens business,
we will become a more broad-based leader in vision care. Importantly, with this
acquisition we will enter cataract surgery – one of the most commonly performed
surgeries and the number one cause of preventable blindness.”
AMO is a global leader in ophthalmic surgery and is known for world-class
intraocular lenses used in cataract surgery. The World Health Organization
estimates that approximately 20 million people are blind from age-related
cataracts and that there are at least 100 million eyes with compromised visual
acuity 視力に影響するcaused by cataracts.
These numbers are steadily rising due to population growth and increasing life
In addition to the cataract business, AMO has advanced laser vision (LASIK)角膜屈折矯正手術
technologies designed to enhance surgeon productivity and correct near
sightedness, far sightedness and astigmatism. The acquisition also includes
AMO’s consumer eye health products – over-the-counter drops for dry eye, as well
as multipurpose solutions and hydrogen peroxide cleaning systems for patients
who wear contact lenses.
The transaction is expected to close in the first quarter of 2017 and would be
modestly accretive immediately to adjusted earnings per share*. The closing is
subject to antitrust clearance and other customary closing conditions. Following
the expected closing, sales will be reported in the Medical Devices segment as a
separate platform within Vision Care. not be considered a replacement for GAAP
The innovation began more than three decades
ago as the ophthalmic research arm of Heyer-Schulte
Medical Optics Center (HSMOC), a division of
American Hospital Supply Corporation. The HSMOC would later change its
name to American Medical Optics and eventually to Advanced
Medical Optics, or AMO, as it is known today.
The company started business in 1976 as a
pioneer in the early development of intraocular lenses (IOLs) for cataract
Throughout the 1980s, AMO became known as a
technology company, introducing innovative new IOLs, the first U.S.-made YAG
laser, and a first-generation phacoemulsification system, for the removal of
cataracts. A later generation of this technology, known as the SOVEREIGN®
System with WHITESTAR® technology, won the prestigious Medical Design
Excellence Silver Award from the Industrial Designers Society of America in 1999
for “excellence in medical product design engineering.”
In 1986, American
Medical Optics was sold to Allergan, Inc. and became known as
Allergan Medical Optics.
A few years later in 1989, the company
brought the first small-incision foldable IOL through the U. S. Food and Drug
Administration (FDA) regulatory process. Foldable lenses were a major advance in
cataract surgery because they made it possible for surgeons to insert the lens
through a small incision, resulting in less trauma to the eye and faster visual
recovery from cataract surgery, from months to days.
In 1997, AMO launched the Array®
IOL, the first multifocal lens to be approved for commercial distribution by the
AMO became an independent company in June
2002 following a spin-off from Allergan.
In 2004, AMO introduced the Verisyse phakic
IOL for treatment of moderate to severe myopia, the first lens of its kind to
receive FDA approval. The company also acquired the TECNIS® and CeeOn®
IOLs, the HEALON® line of viscoelastics and the BAERVELDT®
glaucoma device, marking the company's entrance into the glaucoma market. The
TECNIS® IOL is the first IOL with a modified prolate optic to have a
claim for improved functional vision.
On May 27, 2005, AMO completed the
acquisition of VISX, Incorporated, creating the world’s leading refractive
surgical business, bringing together AMO’s expansive suite of cataract and
refractive surgical products with VISX’s state-of-the-art laser vision
The growth continued in 2007 with the
addition of the industry’s leading wavefront diagnostic system and femotsecond
laser through the acquisitions of WaveFront Sciences and IntraLase Corp.,
These additions give AMO the advanced corneal refractive technologies with the
ability to offer a full systems approach that is without peer in the industry.
In 2009, Advanced
Medical Optics, Inc. was acquired by Abbott Laboratories. Today, AMO is
now Abbott Medical Optics Inc. and operated as a
separate entity within Abbott’s medical device division.
Nov. 25, 2016
Johnson & Johnson Confirms Discussions
with Actelion Regarding Potential Transaction
Johnson & Johnson today confirmed it is
engaged in preliminary discussions with Actelion
Pharmaceuticals Ltd. regarding a potential transaction.
There can be no assurance any transaction
will result from these discussions. Johnson & Johnson does not intend to
make any additional comments regarding these discussions unless and until it
is appropriate to do so, or a formal agreement has been reached.
confirmed today that it has been approached by Johnson & Johnson about a
There can be no
certainty that a transaction will result.
Actelion Ltd. is a
leading biopharmaceutical company focused on the discovery, development and
commercialization of innovative drugs for diseases with significant unmet
Actelion is a
leader in the field of pulmonary arterial hypertension (PAH 肺動脈性肺高血圧症). Our
portfolio of PAH treatments covers the spectrum of disease, from WHO Functional
Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by
health authorities for a number of specialist diseases including Type 1 Gaucher
diseaseゴーシェ病, Niemann-Pick type C diseaseニーマン・ピック病,
Digital Ulcers 指潰瘍
in patients suffering from systemic sclerosis, and
mycosis fungoides type cutaneous T-cell lymphoma菌状息肉腫型
Founded in late
1997, with now over 2,500 dedicated professionals covering all key markets
around the world including Europe, the US, Japan, China, Russia and Mexico,
Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.